Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Yan-Pang Ching Shruthi Narayanan Jeffrey A. Klomp Tamara Isermann Sina Loewe Wen-Hsuan Chang Andrew M. Waters Sheila R. Nicewarner Peña E. Baldelli A. C. Edwards Teresa Börding Run-Wei Yang Craig M. Goodwin Prson Gautam M. Ponz-Sarvisé David Horst Kyle J. Seamon Yong-Xian Zhuang Linh Tran Jing-Jing Jiang Mallika Singh K. Wennerberg E. Petricoin Kirsten L. Bryant Clint A. Stalnecker H. Earp Adrienne D. Cox C. Sers S. Vicent C. Der Bjoern Papke
Aug 2026 · bioRxiv · 0 citations
Biology

TL;DR

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

DOI Semantic Scholar
View source

Similar papers

Open access Aug 2026

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven Cancer

By integrating adaptive response to KRAS inhibition with anti-tumor immunity, AXL represents a mechanistically actionable vulnerability whose inhibition deepens and prolongs responses to both allele-specific and pan-KRAS-targeted therapies.

F. Thege, A. Kramer, Norbert Kreisz et al. · 0 citations
Open access Sep 2026

Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia.

It is demonstrated that compensatory AKT activation limits the efficacy of cabozantinib in ALL and the combination of cabozantinib and capivasertib as a promising therapeutic strategy for refractory ALL is established.

Hai-Hong Gao, Yi Zhan, Miao-Ying Bao et al. · 0 citations
Open access Aug 2026

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

XPO1 inhibitor Eltanexor enhances the efficacy and durability of KRAS and pan-RAS inhibition in PDAC models and provides a preclinical rationale for clinically evaluating Eltanexor in combination with RAS-targeted therapies to delay or overcome adaptive resistance in KRAS-mutant PDAC.

H. Y. Khan, M. Al-Hallak, A. Aboukameel et al. · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations
Sep 2026

Abstract B104: Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing

Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...

Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.